AKT-eNOS-NO pathway mediates spontaneous portosystemic shunts and therapeutic efficacy of SC79 in cirrhosis

Figure 1 Higher incidence of decompensation and mortality in cirrhotic patients with spontaneous portosystemic shunts. A: Representative imaging of splenorenal shunt; B: Representative imaging of gastrorenal shunt; C: Representative imaging of umbilical vein recanalization; D: Representative imaging of left gastric-azygos/hemiazygos vein shunt; E: Model for End-stage Liver Disease score in the spontaneous portosystemic shunts (SPSS) and non-SPSS groups at baseline; F: Child-Pugh score in the SPSS and non-SPSS groups at baseline; G: Child-Pugh grade in the SPSS and non-SPSS groups at baseline; H: Cumulative incidence of esophagogastric variceal bleeding during follow-up; I: Cumulative incidence of portal vein thrombosis during follow-up; J: Cumulative incidence of hepatic encephalopathy during follow-up; K: Cumulative incidence of ascites during follow-up; L: Cumulative incidence of hepatocellular carcinoma during follow-up; M: Cumulative incidence of mortality during follow-up. MELD: Model for End-stage Liver Disease; EGVB: Esophagogastric variceal bleeding; SPSS: Spontaneous portosystemic shunts.